Clinical trialNCT01339091CompletedPhase 3Interventional

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

SponsorDurata Therapeutics Inc., an affiliate of Allergan plcEnrollment573AbscessCellulitisSurgical Site InfectionWound Infection

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Michael Dunne, MD
Durata Therapeutics Inc., an affiliate of Allergan plc
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

91 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Durata Study Site
Winnipeg, Manitoba, Canada
Durata Study Site
Trois-Rivières, Quebec, Canada

Croatia

Durata Study Site
Dubrovnik, Croatia
Durata Clinical Site
Slavonski Brod, Croatia
Durata Study Site
Zagreb, Croatia
Durata Study Site
Zagreb, Croatia

Georgia

Durata Clinical Site
Tbilisi, Georgia

Germany

Durata Study Site
Bochum, Germany
Durata Study Site
Münster, Germany

Poland

Durata Study Site
Krakow, Poland
Durata Study Site
Legionowo, Poland
Durata Study Site
Warsaw, Poland
Durata Study Site
Wroclaw, Poland

Russia

Durata Study Site
Kharkiv, Ukraine, Russia
Durata Study Site
Kyiv City, Ukraine, Russia
Durata Clinical Site
Moscow, Russia
Durata Study Site
Moscow, Russia
Durata Study Site
Moscow, Russia
Durata Study Site
Perm, Russia
Durata Clinical Site
Saint Petersburg, Russia
Durata Study Site
Saint Petersburg, Russia
Durata Study Site
Saint Petersburg, Russia
Durata Study Site
Saint Petersburg, Russia
Durata Study Site
Saint Petersburg, Russia
Durata Study Site
Saratov, Russia
Durata Study Site
Smolensk, Russia
Durata Study Site
Tomsk, Russia
Durata Study Site
Yekaterinburg, Russia

Ukraine

Durata Study Site
Cherkasy, Ukraine
Durata Study Site
Ivano-Frankivsk, Ukraine
Durata Study Site
Kharkiv, Ukraine
Durata Study Site
Kyiv, Ukraine
Durata Study Site
Kyiv, Ukraine
Durata Study Site
Uzhhorod, Ukraine
Durata Study Site
Zaporizhzhya, Ukraine
Durata Study Site
Zhytomyr, Ukraine

United States

Durata Study Site
Anaheim, California, United States
Durata Study Site
Azusa, California, United States
Durata Study Site
Bellflower, California, United States
Durata Study Site
Buena Park, California, United States

51 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2011
Primary completion: 30 Sept 2012
Completion: 30 Nov 2012
Last update posted: 31 Jan 2014
Registered enrollment: 573
Registry id: NCT01339091

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.